Details:

Alternative Title:
Open Forum Infect Dis
Personal Author:
Latner, Donald R ; Parker Fiebelkorn, Amy ; McGrew, Marcia ; Williams, Nobia J ; Coleman, Laura A ; ... More +
Latner, Donald R ; Parker Fiebelkorn, Amy ; McGrew, Marcia ; Williams, Nobia J ; Coleman, Laura A ; McLean, Huong Q ; Rubin, Steven ; Hickman, Carole J Less -
Description:
Background

Recent mumps outbreaks among 2-dose measles mumps rubella (MMR) vaccine recipients have raised questions regarding the potential benefits of a third dose of vaccine (MMR3). If MMR3 provides a sustained elevation in mumps antibody, it may be beneficial for certain at-risk groups or as an outbreak control measure.

Methods

Sera were collected immediately prior to MMR3 and at 1 month and 1 year post-MMR3 from 656 healthy adults aged 18–28 years in a nonoutbreak setting. Immunoglobulin G (IgG) was measured by enzyme-linked immunosorbent assay (ELISA) using whole mumps virus (commercial ELISA), hemagglutinin (HN; major neutralizing target), and nucleoprotein (NP; immunodominant) antigens. ELISA measurements were compared with in vitro plaque reduction neutralization (PRN) titers, and baseline antibody was compared with post-MMR3 levels.

Results

There were modest but statistically significant (P < .05) increases in mumps antibody at 1 month post-MMR3 by all 3 ELISA methods and by PRN titer. At 1 year post-MMR3, mumps antibody declined toward baseline but remained elevated (P < .05). The correlation between PRN titers and ELISA measurements was poor (r2 = .49), although sera with the highest amount of HN IgG also had the highest PRN titers.

Conclusions

Individuals with the lowest baseline PRN titers had the largest increase in frequency of samples that became positive for HN and NP by ELISA. A third dose of MMR may benefit certain individuals with a low level of mumps virus–neutralizing antibody, especially in the context of an outbreak or other high-risk setting. Additionally, poor correlation among serologic tests does not allow effective prediction of PRN titer by ELISA.


Subjects:
[+]
Hemagglutinin Immunization Major Article Mumps Mumps Immunogenicity Nucleoprotein Third-dose Measles Mumps Rubella (MMR) Vaccine Vaccine Preventable Disease
Source:
Open Forum Infect Dis. 2017; 4(4).
Pubmed ID:
29308410
Pubmed Central ID:
PMC5751044
Document Type:
Journal Article
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:55c6bb2f4afda4c2d07b0f97590d7fb6ddf99e80fbdd98c13aceff35df23dc6c
Download URL:
https://stacks.cdc.gov/view/cdc/50764/cdc_50764_DS1.pdf
File Type:

Supporting Files

• 	ofx263.nxml	xml
  	ofx26301.gif	gif
  	ofx26301.jpg	jpeg
  	ofx26302.gif	gif
  	ofx26302.jpg	jpeg
  	ofx26303.gif	gif
  	ofx26303.jpg	jpeg

More +